Strategic applications of gene expression: From drug discovery/development to bedside

AAPS Journal

Volumn 15, Issue 2, 2013, Pages 427-437

  Bai, Jane P F ^a   Alekseyenko, Alexander V ^b   Statnikov, Alexander ^b   Wang, I Ming ^c   Wong, Peggy H ^c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

clinical molecular signatures; molecular signatures of disease; signature genes; target engagement; toxicological pathways

Indexed keywords

ATAZANAVIR; BORTEZOMIB; CARFILZOMIB; CIMETIDINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; EVEROLIMUS; HEPATITIS A VACCINE; INFLUENZA VACCINE; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA1 ANTIBODY; INTERLEUKIN 14; LETROZOLE; MENINGOCOCCUS VACCINE; MESSENGER RNA; PNEUMOCOCCUS VACCINE; RABIES VACCINE; RITONAVIR; TOPIRAMATE; UNCLASSIFIED DRUG; VINCRISTINE;

ASPN GENE; BREAST CANCER; DIABETIC NEPHROPATHY; DISEASE MARKER; DNA SEQUENCE; DRUG ABSORPTION; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; ENTERITIS; GENE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MUTATION; GENETIC TRANSCRIPTION; GREM1 GENE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IRF1 GENE; LUNG NON SMALL CELL CANCER; MATN3 GENE; NEUROPATHY; NONHUMAN; OSTEOARTHRITIS; REVIEW; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH ULCER; STRUCTURE ACTIVITY RELATION; UPREGULATION; VACCINATION;

ANIMALS; DRUG DISCOVERY; DRUG THERAPY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; PATIENT SAFETY; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84877045010     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9447-1     Document Type: Review

References (101)

1. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929-35. doi: 10.126/science. 1132939.
2. Mahadevan B, Snyder RD, Waters MD, Benz RD, Kemper RA, Tice RR, et al. Genetic toxicology in the 21st century: Reflections and future directions. Environ Mol Mutagen. 2011;52(5):339-54. doi: 10.1002/em.20653.
3. Liu H, D'Andrade P, Fulmer-Smentek S, Lorenzi P, Kohn KW, Weinstein JN, et al. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther. 2010;9(5):1080-91. doi: 10.1158/535-7163.MCT-09- 0965.
4. Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, Schreiber SL, et al. Large-scale chemical dissection of mitochondrial function. Nat Biotechnol. 2008;26(3):343-51. doi: 10.038/nbt.
5. Connectivity Map. http://wwwbroadinstituteorg/cmap/. Accessed July 2012.
6. Developing Orphan Products: FDA and Rare Disease Day. http://wwwfdagov/ForIndustry/DevelopingProductsforRareDiseasesConditions/ ucm239698htm. Accessed July 2012.
7. Kao KJ, Chang KM, Hsu HC, Huang AT. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: Implications for treatment optimization. BMC Cancer. 2011;11:143. doi: 10.1186/471-2407-11-143.
8. Mehta R, Jain RK, Badve S. Personalized medicine: The road ahead. Clin Breast Cancer. 2011;11(1):20-6. doi: 10.3816/CBC.2011.n.004. Review.
9. Mizuarai S, Yamanaka K, Itadani H, Arai T, Nishibata T, Hirai H, et al. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer. 2009;8:34. doi: 10.1186/476-4598-8-34.
10. Liebler DC, Guengerich FP. Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov. 2005;4(5):410-20. doi: 10.1038/nrd720.
11. D'Haeseleer P. How does gene expression clustering work? Nat Biotechnol. 2005;23(12):1499-501. doi: 10.038/nbt205.
12. Yang X, Regan K, Huang Y, Zhang Q, Li J, Seiwert TY, et al. Single sample expression-anchored mechanisms predict survival in head and neck cancer. PLoS Comput Biol. 2012;8(1):e1002350. doi: 10.1371/journal.pcbi.
13. KEGG (Kyoto Encyclopedia of Genes and Genomes). http://wwwgenomejp/kegg. Accessed July 2011.
14. Reactome. http://wwwreactomeorg/ReactomeGWT/entrypointhtml. Accessed January 2012.
15. Kirouac DC, Saez-Rodriguez J, Swantek J, Burke JM, Lauffenburger DA, Sorger PK. Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks. BMC Syst Biol. 2012;6(1):29. doi: 10.1186/752-0509-6-29.
16. Alexopoulos LG, Saez-Rodriguez J, Cosgrove BD, Lauffenburger DA, Sorger PK. Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes. Mol Cell Proteomics. 2010;9(9):1849-65. doi: 10.074/mcp.M110. 000406.
17. Madhamshettiwar PB, Maetschke SR, Davis MJ, Reverter A, Ragan MA. Gene regulatory network inference: Evaluation and application to ovarian cancer allows the prioritization of drug targets. Genome Med. 2012;4(5):41. doi: 10.1186/gm340.
18. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med. 2011;3(96):96ra77. doi: 10.1126/scitranslmed.3001318.
19. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med. 2011;3(96):96ra76. doi: 10.1126/scitranslmed. 3002648.
20. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-7. doi: 10.1038/nature11003.
21. Novershtern N, Subramanian A, Lawton LN, Mak RH, Haining WN, McConkey ME, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell. 2011;144(2):296-309. doi: 10.1016/j.cell.2011.01.004.
22. Campbell JD, Spira A, Lenburg ME. Applying gene expression microarrays to pulmonary disease. Respirology. 2011;16(3):407-18. doi: 10.1111/j.440-843.2011. 01942.x. Review.
23. Zeskind JE, Lenburg ME, Spira A. Translating the COPD transcriptome: Insights into pathogenesis and tools for clinical management. Proc Am Thorac Soc. 2008;5(8):834-41. doi: 10.1513/pats.200807-074TH.
24. Jenner RG, Young RA. Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol. 2005;3(4):281-94. doi: 10.1038/nrmicro126.
25. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008;452(7187):564-70. doi: 10.1038/nature06915.
26. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, et al. A modular analysis framework for blood genomics studies: Application to systemic lupus erythematosus. Immunity. 2008;29(1):150-64. doi: 10.1016/j.immuni.2008.05. 012.
27. Banchereau R, Jordan-Villegas A, Ardura M, Mejias A, Baldwin N, Xu H, et al. Host immune transcriptional profiles reflect the variability in clinical disease manifestations in patients with Staphylococcus aureus infections. PLoS One. 2012;7(4):e34390. doi: 10.1371/journal.pone.0034390.
28. Puig O, Wang IM, Cheng P, Zhou P, Roy S, Cully D, et al. Transcriptome profiling and network analysis of genetically hypertensive mice identifies potential pharmacological targets of hypertension. Physiol Genomics. 2010;42A(1):24-32. doi: 10.1152/physiolgenomics.00010.2010.
29. Yang Y, Adelstein SJ, Kassis AI. Integrated bioinformatics analysis for cancer target identification. Methods Mol Biol. 2011;719:527-45. doi: 10.1007/978-1-61779-027-0-25.
30. Chen Y, Zhu J, Lum PY, Yang X, Pinto S, MacNeil DJ, et al. Variations in DNA elucidate molecular networks that cause disease. Nature. 2008;452(7186):429-35. doi: 10.1038/nature06757.
31. Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, et al. Genetics of gene expression and its effect on disease. Nature. 2008;452(7186):423-8. doi: 10.1038/nature06758.
32. Wang IM, Zhang B, Yang X, Zhu J, Stepaniants S, Zhang C, et al. Systems analysis of eleven rodent disease models reveals an inflammatome signature and key drivers. Mol Syst Biol. 2012;8:594.
33. Yanagisawa S, Sugiura H, Yokoyama T, Yamagata T, Ichikawa T, Akamatsu K, et al. The possible role of hematopoietic cell kinase in the pathophysiology of COPD. Chest. 2009;135(1):94-101. doi: 10.1378/chest.07-3020.
34. Lee F, Fandi A, Voi M. Overcoming kinase resistance in chronic myeloid leukemia. Int J Biochem Cell Biol. 2008;40(3):334-43.
35. Paloneva J, Kestila M, Wu J, Salminen A, Bohling T, Ruotsalainen V, et al. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet. 2000;25(3):357-61. doi: 10.1038/77153.
36. Thrash JC, Torbett BE, Carson MJ. Developmental regulation of TREM2 and DAP12 expression in the murine CNS: Implications for Nasu-Hakola disease. Neurochem Res. 2009;34(1):38-45. doi: 10.1007/s11064-008-9657-1.
37. O'Neill LA. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov. 2006;5(7):549-63. doi: 10.1038/nrd2070.
38. Lum PY, He YD, Slatter JG, Waring JF, Zelinsky N, Cavet G, et al. Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia. Genomics. 2007;90(4):464-73. doi: 10.1016/j.ygeno.2007.06.004.
39. Bhat KP, Greer SF. Proteolytic and non-proteolytic roles of ubiquitin and the ubiquitin proteasome system in transcriptional regulation. Biochim Biophys Acta. 2011;1809(2):150-5. doi: 10.1016/j.bbagrm.2010.11.006.
40. Waring JF, Ciurlionis R, Marsh K, Klein LL, Degoey DA, Randolph JT, et al. Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia. Arch Toxicol. 2010;84(4):263-70. doi: 10.1007/s00204-010-0527-7.
41. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, Zhu Z, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med. 2002;8(8):885-9. doi: 10.1038/nm734.
42. Hershey GK. IL-13 receptors and signaling pathways: An evolving web. J Allergy Clin Immunol. 2003;111(4):677-90. Quiz 91.
43. Kole R, Krainer AR, Altman S. RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11(2):125-40. doi: 10.1038/nrd3625. Review.
44. Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K, et al. Off-target effects by siRNA can induce toxic phenotype. RNA. 2006;12(7):1188-96. doi: 10.261/rna.28106.
45. Fucini RV, Haringsma HJ, Deng P, Flanagan WM, Willingham AT. Adenosine modification may be preferred for reducing siRNA immune stimulation. Nucleic Acid Ther. 2012;22(3):205-10. doi: 10.1089/nat.2011.0334.
46. Yuan Z, Wu X, Liu C, Xu G, Wu Z. Asymmetric siRNA: new strategy to improve specificity and reduce off-target gene expression. Hum Gene Ther. 2012;23(5):521-32. doi: 10.1089/hum.2011.145.
47. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA. 2006;12(7):1197-205. doi: 10.261/rna.30706.
48. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 2003;21(6):635-7. doi: 10.1038/nbt831.
49. Anderson E, Boese Q, Khvorova A, Karpilow J. Identifying siRNA-induced off-targets by microarray analysis. Methods Mol Biol. 2008;442:45-63. doi: 10.1007/978-1-59745-191-8-4.
50. Sommerer C, Hartschuh W, Enk A, Meuer S, Zeier M, Giese T. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant. 2008;22(5):549-54. doi: 10.1111/j.399-0012.2008.00819.x.
51. Billing H, Breil T, Schmidt J, Tonshoff B, Schmitt C, Giese T, et al. Pharmacodynamic monitoring by residual NFAT-regulated gene expression in stable pediatric liver transplant recipients. Pediatr Transplant. 2012;16(2):187-94. doi: 10.1111/j.399-3046.2012.01660.x.
52. Locatelli G, Bosotti R, Ciomei M, Brasca MG, Calogero R, Mercurio C, et al. Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study. Mol Cancer Ther. 2010;9(5):1265-73. doi: 10.58/535-7163.MCT-09-1163.
53. Rockett JC, Burczynski ME, Fornace AJ, Herrmann PC, Krawetz SA, Dix DJ. Surrogate tissue analysis: monitoring toxicant exposure and health status of inaccessible tissues through the analysis of accessible tissues and cells. Toxicol Appl Pharmacol. 2004;194(2):189-99.
54. Berkofsky-Fessler W, Nguyen TQ, Delmar P, Molnos J, Kanwal C, DePinto W, et al. Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. Mol Cancer Ther. 2009;8(9):2517-25. doi: 10.1158/535-7163.MCT-09-0083.
55. Boni JP, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J, et al. Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther. 2005;77(1):76-89. doi: 10.1016/j.clpt.2004.08.025.
56. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391.
57. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res. 2004;10(23):8059-67. doi: 10.1158/078-0432.CCR-04-035.
58. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol. 2007;18(8):1323-8.
59. Zheng M, Lv LL, Cao YH, Liu H, Ni J, Dai HY, et al. A pilot trial assessing urinary gene expression profiling with an mRNA array for diabetic nephropathy. PLoS One. 2012;7(5):e34824. doi: 10.1371/journal.pone.0034824.
60. Affo S, Dominguez M, Lozano JJ, Sancho-Bru P, Rodrigo-Torres D, Morales-Ibanez O, et al. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut. 2012. doi: 10.1136/gutjnl-2011-301146.
61. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: An update with relevance for clinical practice. Lancet. 2011;377(9783):2115-26. doi: 10.1016/S0140-6736(11)60243-2. Review.
62. Kraus VB. Osteoarthritis year 2010 in review: Biochemical markers. Osteoarthr Cartil. 2011;19(4):346-53. doi: 10.1016/j.joca.2011.02.002.
63. Bobinac D, Spanjol J, Zoricic S, Maric I. Changes in articular cartilage and subchondral bone histomorphometry in osteoarthritic knee joints in humans. Bone. 2003;32(3):284-90.
64. Watters JW, Cheng C, Pickarski M, Wesolowski GA, Zhuo Y, Hayami T, et al. Inverse relationship between matrix remodeling and lipid metabolism during osteoarthritis progression in the STR/Ort mouse. Arthritis Rheum. 2007;56(9):2999-3009. doi: 10.1002/art.22836.
65. Kizawa H, Kou I, Iida A, Sudo A, Miyamoto Y, Fukuda A, et al. An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis. Nat Genet. 2005;37(2):138-44. doi: 10.1038/ng496.
66. Gazzerro E, Pereira RC, Jorgetti V, Olson S, Economides AN, Canalis E. Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology. 2005;146(2):655-65. doi: 10.1210/en.2004-0766.
67. Pullig O, Tagariello A, Schweizer A, Swoboda B, Schaller P, Winterpacht A. MATN3 (matrilin-3) sequence variation (pT303M) is a risk factor for osteoarthritis of the CMC1 joint of the hand, but not for knee osteoarthritis. Ann Rheum Dis. 2007;66(2):279-80. doi: 10.1136/ard.2006.058263.
68. van der Weyden L, Wei L, Luo J, Yang X, Birk DE, Adams DJ, et al. Functional knockout of the matrilin-3 gene causes premature chondrocyte maturation to hypertrophy and increases bone mineral density and osteoarthritis. Am J Pathol. 2006;169(2):515-27. doi: 10.2353/ajpath.006.050981.
69. Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: A prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010;11(11):1057-65. doi: 10.1016/S1470-2045(10)-0.
70. Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: A link to clinical adverse events. Clin Cancer Res. 2011;17(9):2734-43. doi: 10.1158/078-0432.CCR-10-1950.
71. Vande Walle L, Lamkanfi M, Vandenabeele P. The mitochondrial serine protease HtrA2/Omi: An overview. Cell Death Differ. 2008;15(3):453-60. doi: 10.1038/sj.cdd.4402291.
72. Momose H, Mizukami T, Ochiai M, Hamaguchi I, Yamaguchi K. A new method for the evaluation of vaccine safety based on comprehensive gene expression analysis. J Biomed Biotechnol. 2010;2010:361841. doi: 10.1155/2010/.
73. Hamaguchi I, Imai J, Momose H, Kawamura M, Mizukami T, Naito S, et al. Application of quantitative gene expression analysis for pertussis vaccine safety control. Vaccine. 2008;26(36):4686-96. doi: 10.1016/j.vaccine.2008.06. 086.
74. Mizukami T, Imai J, Hamaguchi I, Kawamura M, Momose H, Naito S, et al. Application of DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation. Vaccine. 2008;26(18):2270-83. doi: 10.1016/j.vaccine.2008.02.031.
75. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008;205(13):3119-31. doi: 10.1084/jem.20082292.
76. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009;10(1):116-25. doi: 10.1038/ni.688.
77. Palermo RE, Patterson LJ, Aicher LD, Korth MJ, Robert-Guroff M, Katze MG. Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: Insights into mechanisms of vaccine efficacy. J Virol. 2011;85(2):1099-116. doi: 10.128/JVI.01522-10.
78. Balas C, Kennel A, Deauvieau F, Sodoyer R, Arnaud-Barbe N, Lang J, et al. Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains. J Infect Dis. 2011;203(1):103-8. doi: 10.1093/infdis/jiq022.
79. Huang E, Ishida S, Pittman J, Dressman H, Bild A, Kloos M, et al. Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet. 2003;34(2):226-30. doi: 10.1038/ng167.
80. Ganter B, Giroux CN. Emerging applications of network and pathway analysis in drug discovery and development. Curr Opin Drug Discov Devel. 2008;11(1):86-94.
81. Reif DM, McKinney BA, Motsinger AA, Chanock SJ, Edwards KM, Rock MT, et al. Genetic basis for adverse events after smallpox vaccination. J Infect Dis. 2008;198(1):16-22. doi: 10.1086/588670.
82. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B, et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell. 2012;21(4):547-62. doi: 10.1016/j.ccr.2012.02. 028.
83. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Miriami E, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148(6):1293-307. doi: 10.016/j.cell.2012.02.009.
84. Field LA, Love B, Deyarmin B, Hooke JA, Shriver CD, Ellsworth RE. Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women. Cancer. 2012;118(5):1334-44. doi: 10.002/cncr.26405.
85. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Margeson D, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(4):596-604. doi: 10.200/JCO.2009.25.1496.
86. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst. 2011;103(3):264-72. doi: 10.1093/jnci/djq524.
87. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A. 2010;107(15):6994-9. doi: 10.1073/pnas.
88. Jonsson G, Staaf J, Vallon-Christersson J, Ringner M, Holm K, Hegardt C, et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res. 2010;12(3):R42. doi: 10.1186/bcr2596.
89. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005;102(38):13550-5. doi: 10.1073/pnas.
90. Bai JP, Bell R, Buckman S, Burckart GJ, Eichler HG, Fang KC, et al. Translational biomarkers: From preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop. AAPS J. 2011;13(2):274-83. doi: 10.1208/s12248-011-9265-x.
91. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther. 2007;81(1):104-7. doi: 10.1038/sj.clpt.6100017.
92. Zhou HH, Chin CN, Wu M, Ni W, Quan S, Liu F, et al. Suppression of PC-1/ENPP-1 expression improves insulin sensitivity in vitro and in vivo. Eur J Pharmacol. 2009;616(1-3):346-52. doi: 10.1016/j.ejphar.2009.06.057.
93. Uehara T, Ono A, Maruyama T, Kato I, Yamada H, Ohno Y, et al. The Japanese toxicogenomics project: Application of toxicogenomics. Mol Nutr Food Res. 2010;54(2):218-27. doi: 10.1002/mnfr.200900169.
94. PharmGKB. The Pharmacogenomics Knowledgebase. http://www.pharmgkb.org. Accessed July 2011.
95. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science. 2008;321(5886):263-6. doi: 10.1126/science.1158140.
96. Toyoshiba H, Sawada H, Naeshiro I, Horinouchi A. Similar compounds searching system by using the gene expression microarray database. Toxicol Lett. 2009;186(1):52-7. doi: 10.1016/j.toxlet.2008.08.009.
97. Lytkin NI, McVoy L, Weitkamp JH, Aliferis CF, Statnikov A. Expanding the understanding of biases in development of clinical-grade molecular signatures: A case study in acute respiratory viral infections. PLoS One. 2011;6(6):e20662. doi: 10.1371/journal.pone.0020662.
98. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst. 2003;95(1):14-8.
99. Statnikov A, Aliferis CF. Analysis and computational dissection of molecular signature multiplicity. PLoS Comput Biol. 2010;6(5):e1000790. doi: 10.1371/journal.pcbi.
100. Qiu X, Brooks AI, Klebanov L, Yakovlev N. The effects of normalization on the correlation structure of microarray data. BMC Bioinforma. 2005;6:120. doi: 10.1186/471-2105-6-120.
101. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst. 2007;99(2):147-57. doi: 10.1093/jnci/djk018.